immuno-oncology
Bristol Myers Squibb Marks Milestone with FDA Approval of Subcutaneous Opdivo Qvantig
Bristol Myers Squibb, Opdivo, subcutaneous administration, FDA approval, cancer treatment, immuno-oncology, PD-1 inhibitor.
Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals for $558.4 Million
Coherus BioSciences, Udenyca, Intas Pharmaceuticals, pegfilgrastim-cbqv, immuno-oncology, pharmaceutical deal
Ipsen and Biomunex Partner on First-in-Class MAIT Cell Engager for Solid Tumors in $610M Deal
Ipsen, Biomunex, MAIT cell engager, T cell engager, solid tumors, immuno-oncology, BMX-502, BiXAb technology, GPC3 tumor antigen.
A Decade of Progress: Immuno-oncology on the Cusp of a New Era
Immuno-oncology, checkpoint inhibitors, bispecific antibodies, cancer treatment, immunotherapy, cancer research, future of cancer care.
iTeos-GSK’s TIGIT Combination Demonstrates Superior Tumor Shrinkage in Phase 2 Trial
iTeos Therapeutics, GSK, TIGIT, EOS-448, Jemperli, Phase 2 trial, tumor shrinkage, immuno-oncology, cancer treatment
GSK Secures Broad Label Expansion for Jemperli in First-Line Endometrial Cancer
GSK, Jemperli, dostarlimab, endometrial cancer, FDA approval, chemotherapy, immuno-oncology, Keytruda, Merck
Boehringer Ingelheim Acquires Nerio Therapeutics for $1.3 Billion, Expanding Immuno-Oncology Portfolio
Boehringer Ingelheim, Nerio Therapeutics, Immuno-Oncology, Cancer Treatment, Acquisition, Small Molecule Inhibitors
ASCO24: Nimbus Unveils Promising Early Data for Next-Generation HPK1 Blocker in IO Therapies
ASCO24, Nimbus, Next-Generation IO Therapies, HPK1 Blocker, Early Data, Cancer Treatment, Immuno-Oncology, Clinical Trials.